This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
health care | 111 |
convalescent plasma | 93 |
acute respiratory | 84 |
respiratory syndrome | 63 |
severe acute | 60 |
mayo clinic | 59 |
coronavirus disease | 57 |
clin proc | 40 |
mayo clin | 40 |
doc id | 39 |
cord uid | 39 |
proc doi | 39 |
novel coronavirus | 36 |
public health | 35 |
united states | 35 |
contact tracing | 32 |
care workers | 31 |
mechanical ventilation | 30 |
new york | 29 |
hospitalized patients | 29 |
severe covid | 25 |
social distancing | 22 |
health organization | 21 |
ill patients | 21 |
syndrome coronavirus | 21 |
world health | 21 |
primary care | 21 |
converting enzyme | 20 |
systematic review | 20 |
infectious diseases | 20 |
respiratory failure | 20 |
risk factors | 19 |
vital signs | 18 |
myocardial injury | 17 |
intensive care | 17 |
critically ill | 17 |
clinical course | 16 |
care providers | 15 |
randomized controlled | 15 |
plasma transfusion | 15 |
disease control | 15 |
emergency department | 15 |
hong kong | 15 |
substance use | 14 |
york city | 14 |
distress syndrome | 14 |
clinical guidance | 14 |
mortality rate | 14 |
respiratory distress | 14 |
avian influenza | 13 |
use disorders | 13 |
healthcare workers | 13 |
high risk | 13 |
lung injury | 13 |
alcohol use | 13 |
care unit | 13 |
segment elevation | 13 |
myocardial infarction | 12 |
hearing loss | 12 |
care delivery | 12 |
use disorder | 12 |
clinical characteristics | 12 |
pd deficiency | 12 |
receptor blockers | 11 |
day mortality | 11 |
patients may | 11 |
cardiovascular disease | 11 |
clinical features | 11 |
clinical trials | 10 |
clinical outcomes | 10 |
patient care | 10 |
cardiac events | 10 |
case series | 10 |
angiotensin converting | 10 |
patients admitted | 10 |
acei arb | 10 |
sud treatment | 10 |
disease spread | 10 |
clinical trial | 10 |
community engagement | 10 |
protective equipment | 10 |
ecg abnormalities | 9 |
personal protective | 9 |
respiratory infections | 9 |
sars coronavirus | 9 |
symptom onset | 9 |
disease severity | 9 |
enzyme inhibitors | 9 |
respiratory vitals | 9 |
mental health | 9 |
expression levels | 9 |
universal masking | 9 |
cytokine storm | 9 |
acute myocardial | 9 |
abnormal respiratory | 9 |
index case | 8 |
atrial fibrillation | 8 |
vital sign | 8 |
heart failure | 8 |
medical school | 8 |
patients hospitalized | 8 |
care organizations | 8 |
tmprss expression | 8 |
viral transmission | 8 |
fatty liver | 8 |
renin angiotensin | 8 |
air travel | 8 |
respiratory vital | 8 |
incubation period | 8 |
critical illness | 8 |
infected patients | 8 |
controlled trial | 8 |
angiotensin system | 8 |
right ventricular | 8 |
infection control | 8 |
controlled trials | 8 |
universal shelter | 8 |
threatening covid | 7 |
cohort study | 7 |
early intubation | 7 |
extensively drug | 7 |
artificial intelligence | 7 |
care system | 7 |
expanded access | 7 |
respiratory rate | 7 |
among patients | 7 |
million people | 7 |
clinic proceedings | 7 |
clinical practice | 7 |
medical education | 7 |
global pandemic | 7 |
supply chain | 7 |
confirmed covid | 7 |
patients infected | 7 |
resistant tuberculosis | 7 |
alcohol consumption | 7 |
transfused patients | 7 |
infectious disease | 7 |
phosphate dehydrogenase | 7 |
angiotensin receptor | 7 |
serious adverse | 7 |
real time | 7 |
respiratory tract | 7 |
case fatality | 6 |
type mi | 6 |
organizing pneumonia | 6 |
standard oxygen | 6 |
immune system | 6 |
family members | 6 |
response rates | 6 |
ejection fraction | 6 |
septic shock | 6 |
increased risk | 6 |
adverse events | 6 |
arb use | 6 |
invasive mechanical | 6 |
task force | 6 |
control measures | 6 |
vulnerable populations | 6 |
repeat testing | 6 |
urgent need | 6 |
addiction treatment | 6 |
virtual visits | 6 |
digital contact | 6 |
east respiratory | 6 |
opioid use | 6 |
healthcare professionals | 6 |
seven days | 6 |
many patients | 6 |
access program | 6 |
middle east | 6 |
resistant tb | 6 |
drug administration | 6 |
coronary artery | 6 |
immune response | 5 |
exposure risk | 5 |
obstructive pulmonary | 5 |
will also | 5 |
anecdotal evidence | 5 |
critical care | 5 |
us fda | 5 |
blood banking | 5 |
methodological standards | 5 |
hypoxemic respiratory | 5 |
respiratory infection | 5 |
left ventricular | 5 |
lack thereof | 5 |
health authorities | 5 |
infected individuals | 5 |
primary endpoints | 5 |
general public | 5 |
index cases | 5 |
surveillance case | 5 |
digital health | 5 |
ace expression | 5 |
recruitment strategy | 5 |
donor recruitment | 5 |
unapproved drugs | 5 |
standard precautions | 5 |
acute hypoxemic | 5 |
immunodeficiency virus | 5 |
outcomes among | 5 |
health emergency | 5 |
treatment considerations | 5 |
reactive protein | 5 |
wall motion | 5 |
human immunodeficiency | 5 |
supportive care | 5 |
angiotensin ii | 5 |
positive pressure | 5 |
smoking cessation | 5 |
increased severity | 5 |
st segment | 5 |
body mass | 5 |
adult inpatients | 5 |
multiple organ | 5 |
adoption rate | 5 |
disease prevention | 5 |
three ecg | 5 |
ventilatory support | 5 |
artery disease | 5 |
influenza virus | 5 |
plasma therapy | 5 |
viral infections | 5 |
interim guidance | 5 |
clinic strategies | 5 |
person treatment | 5 |
york times | 5 |
acute coronary | 5 |
virtual care | 5 |
care systems | 5 |
cardiac injury | 5 |
data capture | 5 |
generating procedures | 5 |
nasal cannula | 5 |
aldosterone system | 5 |
human convalescent | 5 |
oxygen saturation | 5 |
mycobacterium tuberculosis | 5 |
medical care | 5 |
regulatory changes | 5 |
higher mortality | 5 |
future pandemics | 5 |
inflammatory response | 5 |
primary outcome | 5 |
oxygen therapy | 5 |
pulmonary disease | 5 |
polymerase chain | 5 |
invasive ventilation | 5 |
confirmed cases | 5 |
drugs initiative | 5 |
helmet cpap | 5 |
quality evidence | 5 |
first case | 5 |
chronic obstructive | 5 |
susceptible population | 5 |
pressure ventilation | 5 |
prognostic capacity | 5 |
blood donation | 5 |
system inhibitors | 5 |
worse outcomes | 5 |
drug resistance | 5 |
chain reaction | 5 |
eligible donors | 5 |
critical review | 5 |
observational studies | 4 |
recruitment survey | 4 |
retrospective cohort | 4 |
adverse outcomes | 4 |
primary endpoint | 4 |
infectious agents | 4 |
personal sound | 4 |
peer review | 4 |
care may | 4 |
patient satisfaction | 4 |
electronic health | 4 |
care facilities | 4 |
virtual reality | 4 |
lower respiratory | 4 |
nosocomial transmission | 4 |
patients transfused | 4 |
west nile | 4 |
sars cov | 4 |
cardiac imaging | 4 |
evidence base | 4 |
scientific publications | 4 |
tb cases | 4 |
suspected covid | 4 |
clinical presentation | 4 |
within hours | 4 |
immediately available | 4 |
abnormal ecg | 4 |
observational study | 4 |
laboratory values | 4 |
pcr testing | 4 |
human services | 4 |
remains unclear | 4 |
plasma donors | 4 |
pandemic date | 4 |
individuals isolated | 4 |
sound amplification | 4 |
service center | 4 |
chronic kidney | 4 |
spread rapidly | 4 |
past decade | 4 |
group treatment | 4 |
thrombotic events | 4 |
coronary occlusion | 4 |
may also | 4 |
reference verification | 4 |
low risk | 4 |
unclear whether | 4 |
emerging infectious | 4 |
amplification products | 4 |
recovered covid | 4 |
plasma donor | 4 |
significant differences | 4 |
innate immune | 4 |
safety update | 4 |
acral sites | 4 |
severe disease | 4 |
southern china | 4 |
vast majority | 4 |
indicates heart | 4 |
respiratory droplets | 4 |
median time | 4 |
urine drug | 4 |
virus infection | 4 |
reperfusion therapy | 4 |
inflammatory processes | 4 |
national security | 4 |
telehealth services | 4 |
multivariable regression | 4 |
catheterization laboratory | 4 |
dehydrogenase deficiency | 4 |
exposed individuals | 4 |
teaching rounds | 4 |
infected persons | 4 |
blood cell | 4 |
studies published | 4 |
presenting characteristics | 4 |
bird flu | 4 |
nile virus | 4 |
emergency room | 4 |
health systems | 4 |
insufficient evidence | 4 |
kidney disease | 4 |
seattle region | 4 |
reduce mortality | 4 |
organ failure | 4 |
randomized trials | 4 |
laboratory test | 4 |
research electronic | 4 |
african americans | 4 |
surgical environment | 4 |
alcohol dependence | 4 |
normal respiratory | 4 |
dysfunction failure | 4 |
review time | 4 |
one study | 4 |
new human | 4 |
electronic data | 4 |
adoption rates | 4 |
system blockers | 4 |
cognitive biases | 4 |
factors associated | 4 |
medication shortages | 4 |
higher among | 4 |
banking community | 4 |
disease among | 4 |
prognostic value | 4 |
recent study | 4 |
obstructive coronary | 4 |
mortality rates | 4 |
four hours | 4 |
severe cases | 4 |
automated contact | 4 |
abstinence rates | 4 |
regional wall | 4 |
infected pneumonia | 4 |
occurred within | 4 |
within four | 4 |
additional data | 4 |
organ dysfunction | 4 |
susceptible individuals | 4 |
sign abnormalities | 4 |
blood pressure | 3 |
mean age | 3 |
treat covid | 3 |
cardiac arrest | 3 |
convalescent sera | 3 |
increased mortality | 3 |
filtering face | 3 |
death rate | 3 |
hospital staff | 3 |
us department | 3 |
increased susceptibility | 3 |
federal government | 3 |
international collaboration | 3 |
chinese center | 3 |
general population | 3 |
lung function | 3 |
acute lung | 3 |
brief interventions | 3 |
genome sequence | 3 |
viral loads | 3 |
prone position | 3 |
acute ischemic | 3 |
patients including | 3 |
viable option | 3 |
medical attention | 3 |
china characterization | 3 |
absolute lymphocyte | 3 |
influenza pneumonia | 3 |
among older | 3 |
data provide | 3 |
liver disorders | 3 |
many host | 3 |
college admissions | 3 |
serologic testing | 3 |
task forces | 3 |
hospitalization rates | 3 |
preliminary data | 3 |
infectious agent | 3 |
fewer individuals | 3 |
required mechanical | 3 |
epithelial cells | 3 |
diabetes mellitus | 3 |
tract infection | 3 |
first reported | 3 |
confidence interval | 3 |
health records | 3 |
sars outbreak | 3 |
mechanically ventilated | 3 |
type myocardial | 3 |
prevention strategies | 3 |
inflammatory cytokines | 3 |
two contiguous | 3 |
medical students | 3 |
older adults | 3 |
sars returns | 3 |
baseline characteristics | 3 |
quality studies | 3 |
within rows | 3 |
surgical masks | 3 |
created using | 3 |
older males | 3 |
makeshift masks | 3 |
risk stratification | 3 |
eligibility criteria | 3 |
severe illness | 3 |
person care | 3 |
hospitalized adults | 3 |
fatality rates | 3 |
text messaging | 3 |
less accessible | 3 |
states covid | 3 |
office visit | 3 |
standard blood | 3 |
early diagnosis | 3 |
gender disparities | 3 |
recent reports | 3 |
hand hygiene | 3 |
mathematical theory | 3 |
help us | 3 |
spanish influenza | 3 |
respiratory symptoms | 3 |
specific tissues | 3 |
based dashboard | 3 |
long term | 3 |
line drugs | 3 |
great interest | 3 |
many providers | 3 |
based treatment | 3 |
gtex data | 3 |
diseases society | 3 |
health crisis | 3 |
care services | 3 |
expression data | 3 |
care units | 3 |
plasma donation | 3 |
point estimate | 3 |
interested volunteers | 3 |
care institutions | 3 |
hospital admission | 3 |
new digital | 3 |
healthcare provider | 3 |
immune responses | 3 |
extreme outliers | 3 |
us covid | 3 |
human pathogens | 3 |
interactive web | 3 |
hospital mortality | 3 |
significantly higher | 3 |
influenza pandemic | 3 |
face masks | 3 |
contiguous leads | 3 |
nan coronavirus | 3 |
safety indicators | 3 |
admissions personnel | 3 |
data abstraction | 3 |
reports suggest | 3 |
resource allocation | 3 |
south africa | 3 |
working group | 3 |
several reasons | 3 |
telehealth visits | 3 |
hubei province | 3 |
ii receptor | 3 |
randomized clinical | 3 |
vulnerable communities | 3 |
became infected | 3 |
texting interventions | 3 |
city area | 3 |
clinical research | 3 |
induced lung | 3 |
severe sars | 3 |
cancer patients | 3 |
stress disorder | 3 |
training programs | 3 |
negative results | 3 |
clinical specimens | 3 |
chronic illness | 3 |
ventricular hypertrophy | 3 |
current pandemic | 3 |
weak recommendation | 3 |
host cells | 3 |
protease inhibitors | 3 |
paramount importance | 3 |
endothelial dysfunction | 3 |
hearing aids | 3 |
initial report | 3 |
fatality rate | 3 |
ehr implementations | 3 |
even though | 3 |
coronary angiography | 3 |
several factors | 3 |
infection date | 3 |
medical training | 3 |
isolation measures | 3 |
global burden | 3 |
current covid | 3 |
upper respiratory | 3 |
hepatic steatosis | 3 |
randomized trial | 3 |
continuing care | 3 |
frequency modulation | 3 |
china coronavirus | 3 |
successful implementation | 3 |
ventricular overload | 3 |
ccl activation | 3 |
review article | 3 |
ahrf due | 3 |
behavioral health | 3 |
smallpox virus | 3 |
lymphocyte count | 3 |
commercial aircraft | 3 |
surgical area | 3 |
risks associated | 3 |
short supply | 3 |
clinical symptoms | 3 |
mediterranean region | 3 |
late december | 3 |
pressure rooms | 3 |
injectable naltrexone | 3 |
pandemic influenza | 3 |
nationwide analysis | 3 |
surgical mask | 3 |
lactate dehydrogenase | 3 |
liver function | 3 |
hospital sector | 3 |
drug therapy | 3 |
nippv treatment | 3 |
lung infiltrates | 3 |
using telehealth | 3 |
preliminary report | 3 |
drinks per | 3 |
ras inhibitors | 3 |
logistic regression | 3 |
trial results | 3 |
requiring mechanical | 3 |
full lockdown | 3 |
key safety | 3 |
european centre | 3 |
viral infection | 3 |
multiple tissues | 3 |
cardiac catheterization | 3 |
via telehealth | 3 |
targeted self | 3 |
important lessons | 3 |
face mask | 3 |
several studies | 3 |
commonly used | 3 |
severe respiratory | 3 |
user adoption | 3 |
urine test | 3 |
may provide | 3 |
disease pandemic | 3 |
going forward | 3 |
time pressure | 3 |
subsequent testing | 3 |
new call | 3 |
airway pressure | 3 |
among others | 3 |
management strategies | 3 |
related lung | 3 |
pcr assays | 3 |
chinese authorities | 3 |
retrospective case | 3 |
month outcomes | 3 |
pd deficient | 3 |
prone positioning | 3 |
current evidence | 3 |
several countries | 3 |
mitigate disease | 3 |
previous studies | 3 |
motion abnormalities | 3 |
circulating levels | 3 |
cardiac involvement | 3 |
airborne transmission | 3 |
adverse cardiac | 3 |
chest radiograph | 3 |
north america | 3 |
term outcomes | 3 |
clinical settings | 3 |
effective therapies | 3 |
coronavirus pandemic | 3 |
least one | 3 |
patients presenting | 3 |
emerging infections | 3 |
tissue expression | 3 |
invasive positive | 3 |
community members | 3 |
us food | 3 |
reduce exposure | 3 |
donor center | 3 |
drs choo | 3 |
drug efficacy | 3 |
blood donor | 3 |
effective communication | 3 |
drug supply | 3 |
large droplets | 3 |
coronavirus sars | 3 |
health equity | 3 |
data regarding | 3 |
respiratory viral | 3 |
made available | 3 |
several limitations | 3 |
mortality compared | 3 |
clinical improvement | 3 |
traced contacts | 3 |
track covid | 3 |
management guidance | 3 |
clinic blood | 3 |
donate convalescent | 3 |
virtual environment | 3 |
human pathogen | 3 |
fibrillation flutter | 3 |
receptor antagonists | 3 |
circulatory overload | 3 |
diagnostic stewardship | 3 |
poor prognosis | 3 |
lung tissue | 3 |
civilian population | 3 |
donor eligibility | 3 |
injury key | 3 |
host tissues | 3 |
transfusion form | 3 |
presenting vital | 3 |
cardiovascular implications | 2 |
treatment campaign | 2 |
avian strain | 2 |
two respiratory | 2 |
includes sub | 2 |
containing covid | 2 |
hfnc compared | 2 |
particulate air | 2 |
allowed mayo | 2 |
cardiovascular presentations | 2 |
sinus rhythm | 2 |
standard deviation | 2 |
add additional | 2 |
targeting tmprss | 2 |
now known | 2 |
close contacts | 2 |
high efficiency | 2 |
workers caring | 2 |
initiative programs | 2 |
received treatment | 2 |
chronic lymphocytic | 2 |
use ai | 2 |
infection cimetidine | 2 |
processing specimens | 2 |
high mortality | 2 |
infections caused | 2 |
treatment review | 2 |
urine testing | 2 |
potential benefits | 2 |
treatment regimens | 2 |
financial sustainability | 2 |
cytotoxic cd | 2 |
sixth vital | 2 |
people worldwide | 2 |
face piece | 2 |
manage patients | 2 |
rapid clinical | 2 |
unnecessary exposure | 2 |
us hospitals | 2 |
ms indicates | 2 |
virtual interactions | 2 |
health system | 2 |
predictive modeling | 2 |
guide practice | 2 |
exposure alert | 2 |
prognostic factors | 2 |
associated circulatory | 2 |
effort will | 2 |
including patients | 2 |
healthcare organizations | 2 |
hospitalized subjects | 2 |
care setting | 2 |
acei arbs | 2 |
ecg provides | 2 |
known covid | 2 |
acute infectious | 2 |
improper use | 2 |
sobering statistics | 2 |
nippv i | 2 |
initial ecgs | 2 |
receiving medical | 2 |
new vaccine | 2 |
molecular biology | 2 |
communications commission | 2 |
failure vs | 2 |
including lung | 2 |
overall comparable | 2 |
pcr assay | 2 |
sfc hal | 2 |
provided invaluable | 2 |
year inside | 2 |
present study | 2 |
reduce risks | 2 |
virus among | 2 |
common symptoms | 2 |
become known | 2 |
hb fvgem | 2 |
drug prices | 2 |
cc oyiwp | 2 |
highly virulent | 2 |
center team | 2 |
highest expression | 2 |
nbc news | 2 |
requiring intravenous | 2 |
hfpef indicates | 2 |
severity among | 2 |
deficient cells | 2 |
find innovative | 2 |
recruit eligible | 2 |
endotracheal tube | 2 |
severe systemic | 2 |
isolation quarantine | 2 |
nyc health | 2 |
respiratory therapists | 2 |
italian novel | 2 |
reverse transcriptase | 2 |
acep covid | 2 |
clinical procedures | 2 |
oxidative stress | 2 |
graphical representation | 2 |
occurring within | 2 |
sae form | 2 |
determine whether | 2 |
press release | 2 |
virtual meetings | 2 |
death rates | 2 |
cytokine responses | 2 |
patient placement | 2 |
ongoing pandemic | 2 |
workers initially | 2 |
machine learning | 2 |
funding sources | 2 |
site adaptive | 2 |
necrosis factor | 2 |
patients found | 2 |
amoy gardens | 2 |
calculated using | 2 |
almost completely | 2 |
change management | 2 |
patient safety | 2 |
medical interventions | 2 |
exotic african | 2 |
communicable diseases | 2 |
study completion | 2 |
care service | 2 |
rapid development | 2 |
composite outcome | 2 |
potential treatment | 2 |
regulatory barriers | 2 |
box plots | 2 |
guiding resource | 2 |
recent global | 2 |
community developed | 2 |
medical literature | 2 |
using ai | 2 |
liver disease | 2 |
mortality events | 2 |
health interventions | 2 |
provide information | 2 |
met criteria | 2 |
human influenza | 2 |
study provides | 2 |
former soviet | 2 |
differences noted | 2 |
protein kinase | 2 |
may become | 2 |
mg dl | 2 |
expiratory circuit | 2 |
hillbilly elegy | 2 |
enforce isolation | 2 |
virtual medical | 2 |
black man | 2 |
less pronounced | 2 |
silver lining | 2 |
vijay rajaram | 2 |
preserved ejection | 2 |
deaths weekly | 2 |
hypertension hospitalized | 2 |
sars epidemic | 2 |
many health | 2 |
st elevations | 2 |
imaging become | 2 |
rapid triage | 2 |
study protocol | 2 |
group based | 2 |
directly related | 2 |
deceased patients | 2 |
protecting healthcare | 2 |
infection now | 2 |
study including | 2 |
routinely used | 2 |
healthcare system | 2 |
following key | 2 |
current literature | 2 |
medical system | 2 |
bibliographic data | 2 |
resistant staphylococcus | 2 |
neutralizing antibodies | 2 |
aceis arbs | 2 |
cov appears | 2 |
initial test | 2 |
lupus erythematosus | 2 |
dendritic cell | 2 |
segment abnormalities | 2 |
retrospective study | 2 |
treatment programs | 2 |
facilitate patient | 2 |
common rhythm | 2 |
disease center | 2 |
within health | 2 |
substantial body | 2 |
patients using | 2 |
simplest assessment | 2 |
tech methods | 2 |
video based | 2 |
repeated testing | 2 |
tb till | 2 |
flamboyant multiplicity | 2 |
guangdong province | 2 |
airborne spread | 2 |
disease caused | 2 |
manual contact | 2 |
produce ventilators | 2 |
smartphone apps | 2 |
patients without | 2 |
alcoholics anonymous | 2 |
use predictive | 2 |
air filters | 2 |
different breathing | 2 |
national blood | 2 |
primary vehicle | 2 |
growing magnitude | 2 |
intubated patients | 2 |
obstructive sleep | 2 |
developed active | 2 |
outcome beyond | 2 |
similar approach | 2 |
model except | 2 |
dozen countries | 2 |
excellent sheep | 2 |
transmission dynamics | 2 |
probable sars | 2 |
us adults | 2 |
diagnostic test | 2 |
month later | 2 |
studies suggest | 2 |
world context | 2 |
field guide | 2 |
human beings | 2 |
indicates electrocardiogram | 2 |
herpes simplex | 2 |
flu vaccine | 2 |
quickly screen | 2 |
odds ratios | 2 |
directed echocardiogram | 2 |
unmet needs | 2 |
american college | 2 |
per hour | 2 |
compares helmet | 2 |
protection act | 2 |
place measures | 2 |
treatment modalities | 2 |
initial results | 2 |
important marker | 2 |
international concern | 2 |
reduced ejection | 2 |
temporary easing | 2 |
early sars | 2 |
human protein | 2 |
informatics support | 2 |
patient factors | 2 |
help group | 2 |
confirmed symptomatic | 2 |
sars cases | 2 |
red blood | 2 |
sedimentation rate | 2 |
requiring supplemental | 2 |
medical conditions | 2 |
ecg findings | 2 |
virtual worlds | 2 |
engagement activities | 2 |
hemolytic anemia | 2 |
persons infected | 2 |
positive airway | 2 |
pressor support | 2 |
recovering covid | 2 |
high volume | 2 |
initial reports | 2 |
ryan haight | 2 |
personnel alike | 2 |
fm frequency | 2 |
prescribing controlled | 2 |
metabolic syndrome | 2 |
hospital arrival | 2 |
sud patients | 2 |
may result | 2 |
human infection | 2 |
nan i | 2 |
copd indicates | 2 |
health center | 2 |
early data | 2 |
phase iii | 2 |
small intestine | 2 |
african rodents | 2 |
previously published | 2 |
ecg indicates | 2 |
government agencies | 2 |
days since | 2 |
improve quality | 2 |
published articles | 2 |
patients remain | 2 |
separate roofline | 2 |
transmembrane protease | 2 |
better understanding | 2 |
growing evidence | 2 |
function tests | 2 |
indicates millimeters | 2 |
evaluate whether | 2 |
chilblains lupus | 2 |
infected population | 2 |
primary perniosis | 2 |
potentially infectious | 2 |
disease covid | 2 |
acute infection | 2 |
driven methodology | 2 |
elevation depression | 2 |
close monitoring | 2 |
fatal outcome | 2 |
medical records | 2 |
advanced automated | 2 |
data available | 2 |
outcome tended | 2 |
education quarantine | 2 |
microphone lanyard | 2 |
large number | 2 |
lessons learned | 2 |
treating physicians | 2 |
expected benefit | 2 |
transmission speed | 2 |
inhalation anthrax | 2 |
inform exposed | 2 |
surrogate clinical | 2 |
rnaseq based | 2 |
findings need | 2 |
described male | 2 |
potentially deleterious | 2 |
manuscript evaluation | 2 |
bz ovx | 2 |
laboratory markers | 2 |
safety profile | 2 |
lat latency | 2 |
study coronavirus | 2 |
data visualization | 2 |
direct communication | 2 |
will depend | 2 |
described previously | 2 |
fufd ba | 2 |
virtual services | 2 |
study implementation | 2 |
chemical dependency | 2 |
age range | 2 |
telemedicine services | 2 |
remains critical | 2 |
person visits | 2 |
like buprenorphine | 2 |
airborne particles | 2 |
using gtex | 2 |
day period | 2 |
troponin levels | 2 |
testing may | 2 |
one another | 2 |
death toll | 2 |
ill covid | 2 |
health services | 2 |
large health | 2 |
telemedicine options | 2 |
rapid sequence | 2 |
positive end | 2 |
china novel | 2 |
weaponized smallpox | 2 |
pcr detection | 2 |
care personnel | 2 |
contacts will | 2 |
common among | 2 |
even greater | 2 |
among healthcare | 2 |
high levels | 2 |
telehealth visit | 2 |
time locating | 2 |
increasing use | 2 |
infectious respiratory | 2 |
seated within | 2 |
cases reported | 2 |
telemental health | 2 |
severe forms | 2 |
may prove | 2 |
sofa score | 2 |
viral pandemic | 2 |
ecg done | 2 |
understanding risk | 2 |
pilot study | 2 |
emerging data | 2 |
ccl team | 2 |
review panel | 2 |
authorities reported | 2 |
survival function | 2 |
emerging evidence | 2 |
death among | 2 |
specific challenges | 2 |
drug costs | 2 |
filtration mask | 2 |
cumulative incidence | 2 |
tool developed | 2 |
based interventions | 2 |
related serious | 2 |
greatest risk | 2 |
ckd indicates | 2 |
secondary perniosis | 2 |
risk patients | 2 |
sore throat | 2 |
select cases | 2 |
clinical presentations | 2 |
cov replication | 2 |
computed tomography | 2 |
reduced alcohol | 2 |
develop strategies | 2 |
effective triage | 2 |
clinical study | 2 |
emergency orders | 2 |
medical facility | 2 |
pulmonary infiltrates | 2 |
individuals will | 2 |
beta coronaviruses | 2 |
universal containment | 2 |
flow rates | 2 |
emerging pathogens | 2 |
first seven | 2 |
health resources | 2 |
health found | 2 |
guidance continues | 2 |
highly contagious | 2 |
physical distancing | 2 |
risk factor | 2 |
social consequences | 2 |
available early | 2 |
chinese physician | 2 |
cad indicates | 2 |
molecular testing | 2 |
myocardial involvement | 2 |
exchanges per | 2 |
easily applied | 2 |
widespread implementation | 2 |
ventricular ejection | 2 |
dgxn ls | 2 |
infection prevention | 2 |
perspective key | 2 |
providers quickly | 2 |
considerably longer | 2 |
minimal symptoms | 2 |
atlas gtex | 2 |
based recovery | 2 |
us prairie | 2 |
cardiac troponin | 2 |
dna vaccines | 2 |
months later | 2 |
chronic diseases | 2 |
state licensure | 2 |
tumor necrosis | 2 |
patients needing | 2 |
disease transmission | 2 |
significantly lower | 2 |
median systolic | 2 |
best practices | 2 |
expression differences | 2 |
study titles | 2 |
additional prognostic | 2 |
south korea | 2 |
male sex | 2 |
inc incubation | 2 |
eye protection | 2 |
many people | 2 |
educational conferences | 2 |
international cooperation | 2 |
safety metrics | 2 |
better outcomes | 2 |
sauq gp | 2 |
rapidly evolving | 2 |
time pcr | 2 |
pandemic caused | 2 |
patient specimens | 2 |
current approach | 2 |
interested potential | 2 |
invaluable assistance | 2 |
medical centers | 2 |
global public | 2 |
within seven | 2 |
simplex virus | 2 |
digital care | 2 |
body temperature | 2 |
sd indicates | 2 |
inflammatory properties | 2 |
may help | 2 |
famotidine administration | 2 |
early triage | 2 |
accessibility verified | 2 |
inpatient care | 2 |
plasma may | 2 |
testing positive | 2 |
soviet union | 2 |
may make | 2 |
another study | 2 |
icu admission | 2 |
van buskirk | 2 |
solidarity trial | 2 |
using data | 2 |
tract symptoms | 2 |
laboratory services | 2 |
global sars | 2 |
exposed health | 2 |
widely reported | 2 |
disease burden | 2 |
one third | 2 |
sinus tachycardia | 2 |
motion study | 2 |
reduced mortality | 2 |
health competencies | 2 |
pulmonary involvement | 2 |
higher rates | 2 |
potential efficacy | 2 |
also likely | 2 |
significant change | 2 |
older age | 2 |
patients received | 2 |
normal circulating | 2 |
southeast asia | 2 |
required home | 2 |
health infrastructure | 2 |
mask wearing | 2 |
substantive concerns | 2 |
care solutions | 2 |
clinical diagnosis | 2 |
hospitalized covid | 2 |
multidisciplinary team | 2 |
biologic weapon | 2 |
inflammatory state | 2 |
safety network | 2 |
receiving mechanical | 2 |
working conditions | 2 |
home monitoring | 2 |
protein atlas | 2 |
required intubation | 2 |
person transmission | 2 |
strong historical | 2 |
place orders | 2 |
increasing numbers | 2 |
found deaths | 2 |
abstract objective | 2 |
early safety | 2 |
program leadership | 2 |
admission days | 2 |
severity scale | 2 |
antibody titer | 2 |
fibrinolytic therapy | 2 |
data immediately | 2 |
covid respiratory | 2 |
virus transmission | 2 |
additional studies | 2 |
serology test | 2 |
decision making | 2 |
risk drinking | 2 |
invasive care | 2 |
registry analysis | 2 |
recently published | 2 |
heart rate | 2 |
cenr partnerships | 2 |
plasmid dna | 2 |
coronary anatomy | 2 |
ecg remains | 2 |
day outcome | 2 |
included studies | 2 |
outcomes based | 2 |
health departments | 2 |
ace inhibitors | 2 |
redcap consortium | 2 |
wgo pml | 2 |
will allow | 2 |
sex differences | 2 |
america guidelines | 2 |
less effective | 2 |
must consider | 2 |
histamine receptor | 2 |
support strategies | 2 |
mm hr | 2 |
high prevalence | 2 |
prisma guidelines | 2 |
historical precedent | 2 |
aerosol generating | 2 |
plausible face | 2 |
literature review | 2 |
social unrest | 2 |
breathing support | 2 |
mm indicates | 2 |
place order | 2 |
clinical areas | 2 |
evidence based | 2 |
patient interviews | 2 |
reaction testing | 2 |
later stages | 2 |
therapy via | 2 |
approximately million | 2 |
respiratory samples | 2 |
monitoring systems | 2 |
socioeconomic status | 2 |
vitro studies | 2 |
corticosteroid therapy | 2 |
potential explanations | 2 |
basing risk | 2 |
infection rate | 2 |
might also | 2 |
jtcf mz | 2 |
liver diseases | 2 |
ventricular strain | 2 |
will consider | 2 |
systolic heart | 2 |
physician time | 2 |
apneic oxygenation | 2 |
controlled substances | 2 |
agencies will | 2 |
party payers | 2 |
vs mm | 2 |
severity remains | 2 |
convalescent blood | 2 |
face evaluation | 2 |
systematic approach | 2 |
myocardial ischemia | 2 |
million individuals | 2 |
clinical status | 2 |
disease model | 2 |
ecgs done | 2 |
aact app | 2 |
affects outcome | 2 |
rapidly expanding | 2 |
healthcare systems | 2 |
hopefully will | 2 |
peak number | 2 |
high suspicion | 2 |
sound intensity | 2 |
lacks input | 2 |
also limit | 2 |
dedicated covid | 2 |
actively involved | 2 |
via nrb | 2 |
cigarette smoking | 2 |
york described | 2 |
synchronous virtual | 2 |
remain suspended | 2 |
flight crew | 2 |
may benefit | 2 |
public wear | 2 |
potential roles | 2 |
new strain | 2 |
surveillance program | 2 |
three hospitals | 2 |
medical providers | 2 |
new positive | 2 |
protease activity | 2 |
regarding covid | 2 |
rational approach | 2 |
wild birds | 2 |
practice guidelines | 2 |
thrombotic complications | 2 |
admission evolves | 2 |
clinical endpoints | 2 |
african american | 2 |
patient needs | 2 |
preliminary death | 2 |
infection risk | 2 |
disease cardiovascular | 2 |
salivary gland | 2 |
radiographic evidence | 2 |
national healthcare | 2 |
extremely high | 2 |
tissue damage | 2 |
highly pathogenic | 2 |
potential covid | 2 |
healthcare safety | 2 |
engaged research | 2 |
symptomatic conditions | 2 |
blood products | 2 |
saes classified | 2 |
telephone visits | 2 |
treatment centers | 2 |
time period | 2 |
taking acei | 2 |
supplement vitamin | 2 |
us civilian | 2 |
percent increase | 2 |
critical due | 2 |
efficiency particulate | 2 |
fact sheet | 2 |
seafood market | 2 |
andrea kim | 2 |
higher level | 2 |
available resources | 2 |
proven cases | 2 |
tissues may | 2 |
cohort studies | 2 |
locating system | 2 |
conventional oxygen | 2 |
prairie dogs | 2 |
interferon alfa | 2 |
background information | 2 |
literature supporting | 2 |
epidemics contributions | 2 |
roofline exhaust | 2 |
may explain | 2 |
lower mortality | 2 |
mg kg | 2 |
one month | 2 |
kxyu nzp | 2 |
triaging covid | 2 |
depression includes | 2 |
may offer | 2 |
low quality | 2 |
require even | 2 |
become infected | 2 |
coronavirus associated | 2 |
workflow process | 2 |
trace contacts | 2 |
related deaths | 2 |
platform partners | 2 |
required higher | 2 |
substances like | 2 |
order exposures | 2 |
per se | 2 |
clinical evidence | 2 |
respiratory viruses | 2 |
will benefit | 2 |
efficacy study | 2 |
el hz | 2 |
factors identified | 2 |
telemedicine interventions | 2 |
ards due | 2 |
saudi arabia | 2 |
available evidence | 2 |
investigational compounds | 2 |
procedural care | 2 |
potential benefit | 2 |
minority communities | 2 |
haight online | 2 |
essential drugs | 2 |
particulate matter | 2 |
federal levels | 2 |
respiratory disease | 2 |
traditional treatment | 2 |
providing translational | 2 |
validation study | 2 |
patient contact | 2 |
dna based | 2 |
million doses | 2 |
also needed | 2 |
ventilated vs | 2 |
sv zqz | 2 |
currently available | 2 |
make us | 2 |
world greatly | 2 |
laboratory workers | 2 |
transmission among | 2 |
drugs might | 2 |
air dispersion | 2 |
principal investigator | 2 |
concern one | 2 |
young adults | 2 |
studies evaluating | 2 |
location accuracy | 2 |
website key | 2 |
different combinations | 2 |
depressions must | 2 |
research informatics | 2 |
social interactions | 2 |
home induction | 2 |
human disease | 2 |
ards days | 2 |
week later | 2 |
obesity among | 2 |
natural history | 2 |
sequence intubation | 2 |
individuals expected | 2 |
additional information | 2 |
latency period | 2 |
earliest creatinine | 2 |
federal communications | 2 |
similar results | 2 |
loosening restrictions | 2 |
effective vaccine | 2 |
iv alcohol | 2 |
study period | 2 |
multiple studies | 2 |
york department | 2 |
patients seen | 2 |
initial presentation | 2 |
tqjmg qb | 2 |
prospective randomized | 2 |
plasma expanded | 2 |
related saes | 2 |
intubations occurring | 2 |
death due | 2 |
clinical care | 2 |
widely available | 2 |
indicates obstructive | 2 |
indicates standard | 2 |
allelic variants | 2 |
air pressure | 2 |
influenza vaccines | 2 |
trials using | 2 |
international community | 2 |
prevent second | 2 |
five variables | 2 |
currently recommended | 2 |
hfref indicates | 2 |
high patient | 2 |
targeted isolation | 2 |
comprehensive search | 2 |
remained hospitalized | 2 |
trial compares | 2 |
kjq xqs | 2 |
new pandemic | 2 |
clinic laboratories | 2 |
respiratory severity | 2 |
edible birds | 2 |
far higher | 2 |
male gender | 2 |
pandemic progressed | 2 |
regional public | 2 |
millimeter changes | 2 |
may underestimate | 2 |
total covid | 2 |
automated email | 2 |
series acep | 2 |
median oxygen | 2 |
become available | 2 |
ecg abnormality | 2 |
crucial due | 2 |
hospital authority | 2 |
social determinants | 2 |
telehealth program | 2 |
negative air | 2 |
probable covid | 2 |
greater chronic | 2 |
indicates stage | 2 |
utilizing data | 2 |
wuhan experience | 2 |
initial vitals | 2 |
require manufacturers | 2 |
reported age | 2 |
national expanded | 2 |
full manuscript | 2 |
proven covid | 2 |
greatly improve | 2 |
biovigilance component | 2 |
years ago | 2 |
glass opacities | 2 |
nasal swabs | 2 |
pcr test | 2 |
united kingdom | 2 |
sector partnerships | 2 |
indicates milliseconds | 2 |
study drugs | 2 |
presentation ecg | 2 |
socioeconomic disadvantage | 2 |
terminal ileum | 2 |
effective assessment | 2 |
qxkel ww | 2 |
transfusion reactions | 2 |
adaptive immune | 2 |
time first | 2 |
prevention website | 2 |
intravenous famotidine | 2 |
nucleic acid | 2 |
noninvasive positive | 2 |
drug resistant | 2 |
control sars | 2 |
acute phase | 2 |
opioid agonist | 2 |
multivariable logistic | 2 |
users respond | 2 |
large outbreak | 2 |
face treatment | 2 |
lower adoption | 2 |
remains unknown | 2 |
label use | 2 |
series clinical | 2 |
drug shortages | 2 |
corona virus | 2 |
disease course | 2 |
looming threat | 2 |
clinical use | 2 |
safety concerns | 2 |
raising concern | 2 |
problem drinkers | 2 |
infection covid | 2 |
nasopharyngeal swab | 2 |
illness severity | 2 |
home quarantine | 2 |
physician navigators | 2 |
weekly report | 2 |
tuberculosis extensively | 2 |
research shows | 2 |
rapid changes | 2 |
erythrocyte sedimentation | 2 |
tobacco treatment | 2 |
event rate | 2 |
median heart | 2 |
physical examination | 2 |
isolation rooms | 2 |
time rt | 2 |
often require | 2 |
better science | 2 |
pharmacy consumer | 2 |
adverse event | 2 |
potential effects | 2 |
symptomatic infected | 2 |
sick patients | 2 |
evolving covid | 2 |
mechanical ventilatory | 2 |
termed coronavirus | 2 |
sera option | 2 |
major scale | 2 |
time spent | 2 |
potential exposure | 2 |
experience mild | 2 |
state agencies | 2 |
consumer protection | 2 |
facial expressions | 2 |
admitted patients | 2 |
ventilation system | 2 |
vicious cycle | 2 |
order spreading | 2 |
fatality ratio | 2 |
holistic approach | 2 |
tissues associated | 2 |
suggest using | 2 |
virtual health | 2 |
cytokine release | 2 |
state health | 2 |
oxygen flow | 2 |
first time | 2 |
adverse effects | 2 |
us states | 2 |
potentially guiding | 2 |
positive surveillance | 2 |
will discuss | 2 |
thromboembolic events | 2 |
see table | 2 |
age groups | 2 |
ucm frol | 2 |
per drinking | 2 |
underestimate illness | 2 |
median respiratory | 2 |
illness monitoring | 2 |
ambulatory practice | 2 |
expiratory pressure | 2 |
nosocomial infection | 2 |
meet criteria | 2 |
elevated ldh | 2 |
rapid spread | 2 |
identified studies | 2 |
plasma per | 2 |
adaptive trials | 2 |
applied decision | 2 |
also need | 2 |
community partners | 2 |
cabin air | 2 |
rural populations | 2 |
translational research | 2 |
systolic blood | 2 |
nippv hospital | 2 |
right panel | 2 |
continually updated | 2 |
lymphocytic leukemia | 2 |
cdc recommends | 2 |
societal inequities | 2 |
migratory lung | 2 |
screen patients | 2 |
abdominal pain | 2 |
chart review | 2 |
key words | 2 |
public policy | 2 |
drinking day | 2 |
past experience | 2 |
severe obesity | 2 |
particularly poor | 2 |
organized system | 2 |
will require | 2 |
software platform | 2 |
data demonstrate | 2 |
long periods | 2 |
test result | 2 |
health agencies | 2 |
data may | 2 |
current coronavirus | 2 |
white blood | 2 |
input variables | 2 |
rapid review | 2 |
regulatory agencies | 2 |
close proximity | 2 |
younger patients | 2 |
rapid switch | 2 |
health clinical | 2 |
vgw uz | 2 |
sleep apnea | 2 |
supplemental oxygen | 2 |
fibrin deposition | 2 |
carefully charted | 2 |
baseline echocardiogram | 2 |
department presentation | 2 |
data collection | 2 |
presentation affects | 2 |
animal markets | 2 |
also like | 2 |
new treatment | 2 |
become symptomatic | 2 |
first published | 2 |
posttraumatic stress | 2 |
potential donors | 2 |
telehealth including | 2 |
telemedicine will | 2 |
prospective study | 2 |
intravenous pressor | 2 |
complete subsequent | 2 |
reported cases | 2 |
greatly expanded | 2 |
thank andrea | 2 |
higher prognostic | 2 |
mild symptoms | 2 |
individual study | 2 |
stemi activation | 2 |
use equipment | 2 |
bioactive elements | 2 |
white coat | 2 |
face exposure | 2 |
via nasal | 2 |
industry partners | 2 |
indicates chronic | 2 |
transmission occurred | 2 |
viral genome | 2 |
host cell | 2 |
considered positive | 2 |
mass index | 2 |
infection spread | 2 |
events requiring | 2 |
preserve personal | 2 |
multinational registry | 2 |
received mechanical | 2 |
laboratory findings | 2 |
will required | 2 |
study whether | 2 |
staphylococcus aureus | 2 |
user response | 2 |
evidence supporting | 2 |
evidence may | 2 |
based therapy | 2 |
clinic irb | 2 |
study clinical | 2 |
online pharmacy | 2 |
aerosolized generating | 2 |
patients met | 2 |
median temperature | 2 |
aact may | 2 |
elevated troponin | 2 |
interstate spread | 2 |
based tools | 2 |
tb transmission | 2 |
positive covid | 2 |
support center | 2 |
thank vijay | 2 |
especially important | 2 |
essential workers | 2 |
plasma use | 2 |
significant increase | 2 |
detected rapidly | 2 |
isolated contacts | 2 |
alternative approaches | 2 |
fatal outcomes | 2 |
organization website | 2 |
rapidly caused | 2 |
population impacted | 2 |
hemodynamic instability | 2 |
coronary revascularization | 2 |
global health | 2 |
associated coronavirus | 2 |
better prepared | 2 |
may need | 2 |
group therapy | 2 |
ppe personal | 2 |
call attention | 2 |
mainland china | 2 |
cell entry | 2 |
antiviral drugs | 2 |
infected person | 2 |
including video | 2 |
greatly needs | 2 |
decision tool | 2 |
get nowhere | 2 |
laboratory results | 2 |
best evidence | 2 |
rigorous analysis | 2 |
clinical experience | 2 |
limited due | 2 |
unique features | 2 |
initially tested | 2 |
positive cases | 2 |
global data | 2 |
related diseases | 2 |
type diabetes | 2 |
inside college | 2 |
various aspects | 2 |
adipose tissue | 2 |
deficient patients | 2 |
minor salivary | 2 |
unclear symptomatic | 2 |